

LIFE SCIENCE FINANCING SUMMARY

January 2023

Biotech Financing Summary

After ending December on a poor note we can conclude that the total investment activity in the Life Science industry was rather disappointing. Overall, Life Science companies managed to secure 507 financing rounds in the private equity sphere in 2022 with a total value of USD 20,360m. Comparing these figures to the investments made in 2021, one is left open-mouthed. In the previous year, 697 rounds were closed with an aggregated value of USD 39,237m. This is almost double the value of 2022, implying that times have changed and companies need to find other ways to grow their business.

In the private equity market, December represented the worst month of the year, barely reaching the USD 1bn mark. Total funding dropped in all regions around the globe. US-based companies failed to maintain the level of almost USD 2bn in November, closing with financing rounds amounting to USD 784m. This drop is also reflected in the number of rounds registered in America, ending with 17 (Nov: 32). The total value of private equity investments in Europe declined to USD 143m (Nov: USD 147m), while the rest of the world also experienced a lowering to USD 116m (Nov: USD 209). Concerning to the total number of rounds raised in December, Europe completed 7, whereas the rest of the world closed 5 (Chart 1).


After two positive months, the Nasdaq Biotech Index (NBI) opened the last month of the year at 4,361. However, in December 2022 the NBI depreciated by 3.41%, closing the year at 4,213.

The largest share of the total number of financing rounds closed in December 2022 (41%) was again deals above USD 30m, with an average deal value of USD 65.9m. Half of these rounds were composed of Series A, whereas Seed Rounds represented 8% and Series B 42%. Investments between USD 15-30m accounted for 31% of the number of rounds, which is 9 percentage points more than the month before. Moreover, transactions with a volume between USD 5m and 15m represented 24% of the total number of financing rounds. Small-size deals only accounted for 3% of which 100% were Seed Rounds.

Syndax Pharmaceuticals, Inc. led the table in investment value in the last month of 2022 by securing a Post-IPO financing round of USD 172.5m. The company focuses on developing a pipeline of combination therapies in multiple cancer indications. In the private equity sphere, Apogee Therapeutics, LLC., completed the largest round in December 2022, raising USD 149m in Series B financing. It is a biotechnology company engaging in the development of innovative methods for treating immunological and inflammatory disorders. The biggest IPO was yet again rather small this month, with a

USD 15.3m offering of Coya Therapeutics, Inc, a clinical-stage biotechnology company dedicated to developing proprietary medicinal products to modulate the function of regulatory T cells.


Biotech Therapeutic Financing Rounds Private Equity



Source: Biotechgate.com

Chart 1. The graph shows equity financing rounds of private and independent biotech therapeutic & diagnostic companies (not included are IPOs, research grants, and loans). Financing amounts and the number of rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.

Proportion of Number of Rounds by Investment Size




Source: Biotechgate.com

Chart 2. The graph shows the proportion of private equity financing rounds by investment size (not included are IPOs, research grants, and loans), covering 12 months. The dataset includes private Biotech (human therapeutics & diagnostics) companies located worldwide. The value of financing rounds from this month may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.

The Private Equity Rounds by Sector in the US and Europe

The data chart 3 shows that in December 2022, the total financing value in the Biotech and Pharma industry in Europe and the US was USD 1,220m, in Digital Health USD 57m, and in Medical Technology USD 187m. When comparing this to the data for November 2022, it appears that the total financing value in the Biotech and Pharma industry decreased significantly from USD 4,715m to USD 1,220m, representing a 74% decrease. The total amount of financing in Digital Health remained almost the same, raising USD 58m instead of USD 57m in November. On the other hand, the Medical Technology industry increased financing from USD 80m to USD 187m. The number of financing rounds in Europe and America in December 2022 was 52, and in November 2022 it was 92, meaning that there was a decrease of 40 rounds.

Private Equity Rounds by Sector (USA and Europe)




Source: Biotechgate.com

Chart 3. The graph shows private equity financing rounds of life science companies in USA and Europe by the company’s sector and the number of rounds. Not included are IPOs, research grants and loans. Financing amounts and the number of rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.



The Proportion of Number of Rounds by Development Phase of Lead Product

In Q4 2022, 40% of the lead products were in the preclinical stage, 22% in Phase I, 29% in Phase II, and 9% in Phase III. When comparing Q4 2022 to Q3 2022, we can see that these quarters are very similar, only experiencing minor changes. The percentage of drugs in the preclinical stage has declined by 3 percentage points, whereas the proportion of the number of rounds in Phase I increase by 1 percentage point and products in Phase III by 2 percentage points. The percentage of lead products in Phase II remained the same, maintaining the 22% level.



Source: Biotechgate.com


Chart 4. The graph above shows the proportion of the number of private equity financing rounds of biotech companies (human therapeutics and diagnostics) by product development phase. The dataset includes private Biotech (human therapeutics & diagnostics) companies located worldwide. The value of financing rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.



The Proportion of Financing Value (USD) by Development Phase of Lead Product

In Q4 2022, 23% of the financing value by lead product development phase was in the preclinical stage, 22% in Phase I, 38% in Phase II, and 17% in Phase III. When looking at chart 5 and comparing Q3 2022 to Q4 2022, it can be observed that there was a decrease of 3 percentage points of the value of lead products in the preclinical stage as well as a decline in Phase III products from 31% to 17%. However, the proportion of financing value of Phase I and Phase II lead products increased by 4 and 13 percentage points, respectively.

Proportion of Financing Value (USD) by Product Development Phase




Source: Biotechgate.com

Chart 5. The graph above shows the allocation of capital towards various rounds. It shows the proportion of the financing value (in million \$) for private equity financing of biotech companies (human therapeutics and diagnostics) by development phase of the lead product. The dataset includes private Biotech (human therapeutics & diagnostics) companies located worldwide. The value of financing rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.

The Proportion of Average Deal Value (USD) by Development Phase of Lead Product

The proportion of the average deal value in the last quarter of the year (Q4 2022) for companies with their lead product in preclinical trials reached a level of USD 24m (12% of the sum of averages). Products in Phase I averaged at USD 46m (20%), Phase II at USD 62m (27%) and Phase III at USD 91m (41%). Especially the average deal value for products in Phase III made a significant change compared to the previous quarter (Nov: USD 240m). On the other hand, Phase I, Phase II and Phase III lead products gained more size and managed to increase their share by 3, 7, and 14 percentage points (Chart 6).



Source: Biotechgate.com

Chart 6. The graph above reflects the value of rounds by series. It shows the proportion of the average financing value (in million \$) for private equity financing of Biotech companies (human therapeutics and diagnostics) by product development phase. The dataset includes private Biotech (human therapeutics & diagnostics) companies located worldwide. The value of financing rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.

Selected Biotech Financing Highlights December 2022

Apogee Therapeutics raises USD 149m in Series B



Apogee Therapeutics, LLC, a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of people living with immunological and inflammatory disorders, announced the closing of a USD 149m in Series B financing. Proceeds from the financing will be used to support Apogee's plans to advance its lead pipeline program into the clinic in 2023 and expand the leadership, scientific, and clinical teams. The Series B financing was co-led by Deep Track Capital and RTW Investments, LP. Other new investors include funds and accounts advised by Fidelity Management & Research Company, OrbiMed, Perceptive Xontogeny Ventures Fund II, RA Capital Management, and Wellington Management. Founding investors, Fairmount and Venrock Healthcare Capital Partners, also participated in the Series B financing.

[Source / Press release](#)

Solve Therapeutics secures USD 126m in Series A financing round



Solve Therapeutics, Inc., an oncology-focused biopharmaceutical company, announced its initial USD 126m Series A financing was completed with a syndicate of venture capital firms including Matrix Capital Management, Decheng Capital, General Atlantic, and Surveyor Capital/Citadel, each represented on the company's board of directors. The mission is to develop novel antibody-based therapies targeting tumor-specific antigens. The company's formation reunites the former VelosBio Inc. (VelosBio) team, a highly experienced group with a proven ability to rapidly advance innovative therapeutics that address unmet medical needs in the treatment of cancer.

[Source / Press release](#)

Coya Therapeutics announces closing of USD 15.25m IPO



Coya Therapeutics, Inc. (Nasdaq: COYA), a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory T cells, announced the closing of its initial public offering with gross proceeds of approximately of USD 15.25m. The company intends to use substantially all of the net proceeds from the offering to advance its discovery and candidate selection stage programs, its programs in preclinical studies into clinical trials, and for general corporate purposes.


[Source / Press release](#)



Initial Public Offerings of Life Science Companies

The graph shows the total number and value of IPOs in the Life Science industry. In December 2022, two companies operating in the Life Sciences industry received funding through an IPO. Coya Therapeutics, Inc., managed to close the largest deal of the month with total proceeds of USD 15.3m, whereas Lipella Pharmaceuticals, Inc. went public, gaining USD 7m in financing. Looking at the whole year, one can observe that there are significant fluctuations in the financing value of IPOs throughout the year, with the highest amount raised in the first month of the year (USD 1,547m) and the lowest in July (USD 7m). Additionally, the number of IPOs also varies, with the most IPOs taking place in January, February, and April, registering 7 each. The least number of IPOs took place in June, July, October, and November, recording only 1 public offering each. It is worth mentioning that in total for the year, the financing value of IPOs raised was USD 4,078m through 43 IPOs. Following record-breaking years in 2020 and 2021, these numbers are rather shocking, indicating that the IPO market experienced its worst period in ages. Last year, in comparison, the Life Science IPO market registered 205 offerings, amounting to a total of USD 35,767m. Thus, the total value of 2022 represents not more than 11% of the previous year. Factors such as geopolitical instability, high levels of inflation, and increasing global interest rates made the demand for IPOs take a nosedive, leading to a significant decline in the number and value of IPOs (Chart 7).

Life Science Company IPOs Worldwide



Source: Biotechgate.com

Chart 7. The graph contains IPO rounds of life science companies (Biotech, Pharma, MedTech, and Digital Health) from around the world. Financing amounts and the numbers of rounds from previous months may alter as new information on financing rounds is received.

Life Science Financing Rounds Summary December 2022

Source: [Biotechgate](https://www.biotechgate.com)

Company Name	Sector	Amount (in Million USD)	Type of Round	Financing Stage	Ownership	Country
Syndax Pharmaceuticals, Inc.	Biotech - Therapeutics*	172.5	NA	Post-IPO	Publicly listed	USA
Apogee Therapeutics, LLC	Biotech - Therapeutics*	149.0	Series B	Equity (private)	Private	USA
Edgewise Therapeutics, Inc.	Biotech - Therapeutics*	138.0	NA	Post-IPO	Publicly listed	USA
Solve Therapeutics	Biotech - Therapeutics*	126.0	Series A	Equity (private)	Private	USA
Astria Therapeutics, Inc.	Biotech - Therapeutics*	115.0	NA	Post-IPO	Publicly listed	USA
Terns Pharmaceuticals Inc.	Biotech - Therapeutics*	86.3	NA	Post-IPO	Publicly listed	USA
HistoSonics Inc.	Medical Technology	85.0	NA	Convertible loan	Private	USA
Entact Bio	Biotech - Therapeutics*	81.0	Series A	Equity (private)	Private	USA
Synchron, Inc.	Medical Technology	75.0	Series C	Equity (private)	Private	USA
Alpha-9 Theranostics Inc.	Biotech - Therapeutics*	75.0	Series B	Equity (private)	Private	Canada
Sound Agriculture	Biotech - Other	75.0	Series D	Equity (private)	Private	USA
Solid Biosciences Inc.	Biotech - Therapeutics*	75.0	NA	Post-IPO	Publicly listed	USA
ADMA Biologics, Inc.	Biotech - Therapeutics*	69.0	NA	Post-IPO	Publicly listed	USA
August Bioservices	Biotech - R&D Services	65.0	Series B	Equity (private)	Private	USA
Enlaza Therapeutics	Biotech - Therapeutics*	61.0	Seed Round	Equity (private)	Private	USA
SonoThera, Inc.	Biotech - Therapeutics*	60.8	Series A	Equity (private)	Private	USA
Kalvista Pharmaceuticals, Inc.	Biotech - Therapeutics*	58.0	NA	Post-IPO	Publicly listed	USA
Ryvu Therapeutics S.A.	Biotech - Therapeutics*	56.5	NA	Post-IPO	Publicly listed	Poland
Enveda Biosciences	Biotech - Therapeutics*	55.0	Series B	Equity (private)	Private	USA
Minervax ApS	Biotech - Therapeutics*	50.0	NA	Debt financing	Private	Denmark
BillionToOne, Inc.	Biotech - R&D Services	48.5	Other / unknown	Equity (private)	Private	USA

Dantari, Inc.	Biotech - Therapeutics*	47.0	Series A	Equity (private)	Private	USA
Aspen Neuroscience, Inc	Biotech - Therapeutics*	40.0	NA	Debt financing	Private	USA
Gilgamesh Pharmaceuticals, Inc.	Biotech - Therapeutics*	39.0	Series B	Equity (private)	Private	USA
BillionToOne, Inc.	Biotech - R&D Services	35.0	NA	Debt financing	Private	USA
Tellus Therapeutics Inc.	Biotech - Therapeutics*	35.0	Series A	Equity (private)	Private	USA
Third Pole, Inc.	Medical Technology	32.0	Series B	Equity (private)	Private	USA
STORM Therapeutics Ltd	Biotech - Therapeutics*	31.7	Series B	Equity (private)	Private	United Kingdom
Launchpad Therapeutics, Inc.	Biotech - Therapeutics*	30.0	Series A	Equity (private)	Private	USA
ABK Biomedical Inc.	Medical Technology	30.0	Series C	Equity (private)	Private	Canada
Anocca AB	Biotech - Therapeutics*	26.4	NA	Debt financing	Private	Sweden
RxAnte, Inc.	Digital Health	25.0	Other / unknown	Equity (private)	Private	USA
Peroxitech Inc.	Biotech - Therapeutics*	25.0	Series A	Equity (private)	Private	USA
Rejoni, Inc.	Medical Technology	25.0	Series B	Equity (private)	Private	USA
Carrick Therapeutics Ltd.	Biotech - Therapeutics*	25.0	Series C	Equity (private)	Private	Ireland
Vaxxas Pty. Ltd.	Biotech - Therapeutics*	23.0	Series C	Equity (private)	Private	Australia
Minervax ApS	Biotech - Therapeutics*	22.0	Other / unknown	Equity (private)	Private	Denmark
numares AG	Biotech - R&D Services	21.1	Other / unknown	Equity (private)	Private	Germany
numares AG	Biotech - R&D Services	21.1	NA	Debt financing	Private	Germany
DeepUll	Biotech - R&D Services	21.1	NA	Debt financing	Private	Spain
Biomica Ltd.	Biotech - Therapeutics*	20.0	Other / unknown	Equity (private)	Private	Israel
Basecamp Research Ltd.	Biotech - R&D Services	20.0	Series A	Equity (private)	Private	United Kingdom
Sonde Health, Inc.	Digital Health	19.3	Series B	Equity (private)	Subsidiary	USA
PureTech Health	Biotech - Therapeutics*	19.3	Series B	Equity (private)	Publicly listed	USA
BrightSpec, Inc.	Biotech - R&D Services	18.4	Series C	Equity (private)	Private	USA

Protillion Biosciences	Biotech - Therapeutics*	18.0	Series A	Equity (private)	Private	USA
KIYATEC, Inc.	Biotech - R&D Services	18.0	Series C	Equity (private)	Private	USA
Alio Medical	Digital Health	18.0	Series C	Equity (private)	Private	USA
EndoGastric Solutions, Inc.	Medical Technology	18.0	Other / unknown	Equity (private)	Private	USA
OMNY Health	Digital Health	17.0	Series B	Equity (private)	Private	USA
iOncitura SA	Biotech - Therapeutics*	15.8	Other / unknown	Equity (private)	Private	Switzerland
Coya Therapeutics, Inc.	Biotech - Therapeutics*	15.3	NA	Going public / IPO	Publicly listed	USA
PictorLabs, Inc	Digital Health	15.2	Other / unknown	Equity (private)	Private	USA
Angiocrine Bioscience Inc.	Biotech - Therapeutics*	15.0	NA	Grants / government subvention	Private	USA
HistoSonics Inc.	Medical Technology	15.0	NA	Debt financing	Private	USA
Arialys Therapeutics	Biotech - Therapeutics*	14.3	Other / unknown	Equity (private)	Private	USA
LumiraDx Limited	Biotech - Therapeutics*	14.2	NA	Grants / government subvention	Publicly listed	United Kingdom
iThera Medical GmbH	Medical Technology	13.7	Other / unknown	Equity (private)	Private	Germany
Lipogems International	Medical Technology	13.2	Series A	Equity (private)	Private	USA
Enveda Biosciences	Biotech - Therapeutics*	13.0	NA	Debt financing	Private	USA
BehaVR, Inc.	Digital Health	13.0	Series B	Equity (private)	Private	USA
GenSight Biologics S.A	Biotech - Therapeutics*	12.7	NA	Post-IPO	Publicly listed	France
Juno Medical	Digital Health	12.0	Series A	Equity (private)	Private	USA
Vevo Therapeutics	Biotech - R&D Services	12.0	Seed Round	Equity (private)	Private	USA
Infinimmune	Biotech - Therapeutics*	12.0	Seed Round	Equity (private)	Private	USA
Sonio SAS	Medical Technology	10.6	NA	Grants / government subvention	Private	France
Jellagen Ltd	Medical Technology	10.6	Series A	Equity (private)	Private	United Kingdom
HTG Molecular Diagnostics, Inc.	Biotech - R&D Services	10.0	NA	Post-IPO	Publicly listed	USA

Quris Technologies LTD	Digital Health	9.0	Seed Round	Equity (private)	Private	Israel
BiondVax Pharmaceuticals Ltd.	Biotech - Therapeutics*	8.0	NA	Post-IPO	Publicly listed	Israel
RedHill Biopharma Ltd.	Pharma (fully integrated)	8.0	NA	Post-IPO	Publicly listed	Israel
Bactobio Ltd	Biotech - Therapeutics*	7.3	Other / unknown	Equity (private)	Private	United Kingdom
Lipella Pharmaceuticals Inc.	Biotech - Therapeutics*	7.0	NA	Going public / IPO	Publicly listed	USA
Eigen Therapeutics	Biotech - Therapeutics*	7.0	Seed Round	Equity (private)	Private	USA
CrowdHealth, Inc.	Digital Health	6.0	Series A	Equity (private)	Private	USA
Pixelgen Technologies AB	Biotech - R&D Services	6.0	Seed Round	Equity (private)	Private	Sweden
Tetranuron SL	Biotech - Therapeutics*	5.3	Series A	Equity (private)	Private	Spain
CytoSorbents Corporation	Medical Technology	5.0	NA	Debt financing	Publicly listed	USA
Pangea Biomed	Biotech - Therapeutics*	5.0	Seed Round	Equity (private)	Private	Israel
Clene Inc.	Biotech - Therapeutics*	5.0	NA	Debt financing	Publicly listed	USA
Monarch Medical Technologies	Digital Health	5.0	NA	Convertible loan	Private	USA
Baudax Bio, Inc.	Biotech - Therapeutics*	5.0	NA	Post-IPO	Publicly listed	USA
Efemoral Medical	Medical Technology	4.9	Series A	Equity (private)	Private	USA
Parallel Bio	Biotech - Therapeutics*	4.3	Seed Round	Equity (private)	Private	USA
Avisi Technologies, Inc.	Medical Technology	4.1	Seed Round	Equity (private)	Private	USA
Green Bioactives	Biotech - Other	3.2	Seed Round	Equity (private)	Private	United Kingdom
Calidi Biotherapeutics, Inc.	Biotech - Therapeutics*	3.1	NA	Grants / government subvention	Private	USA
Solis Agrosiences	Biotech - Other	3.1	Seed Round	Equity (private)	Private	USA
iOncitura SA	Biotech - Therapeutics*	2.6	NA	Grants / government subvention	Private	Switzerland
Vizabli, Inc.	Digital Health	2.5	Seed Round	Equity (private)	Private	USA
ImVitro	Digital Health	2.5	Seed Round	Equity (private)	Private	France



Avicanna Inc.	Biotech - Therapeutics*	1.8	NA	Post-IPO	Publicly listed	Canada
Berkshire Biomedical Corporation	Medical Technology	1.7	NA	Grants / government subvention	Private	USA
FineHeart SA	Medical Technology	1.6	NA	Grants / government subvention	Private	France
Added Health Ltd.	Digital Health	1.2	Seed Round	Equity (private)	Private	United Kingdom
Warrior Centric Health	Digital Health	1.0	Other / unknown	Equity (private)	Private	USA
ExplorNA Therapeutics	Biotech - Therapeutics*	0.8	NA	Grants / government subvention	Private	Poland
Linshom Management LLC	Medical Technology	0.3	Other / unknown	Equity (private)	Private	USA
Rise Health	Digital Health	NA	Other / unknown	Equity (private)	Private	USA
WishBone Medical, Inc.	Medical Technology	NA	Other / unknown	Equity (private)	Private	USA

Biotech - Therapeutics* = Biotechnology - Therapeutics and Diagnostics

About this summary

The Biotech Financing Summary is published on a monthly basis by Venture Valuation and can be downloaded for free either from our newsletter or from the website www.biotechgate.com/financing

The data used for this summary is taken from Venture Valuation's global life science database Biotechgate, if not explicitly stated otherwise. Biotechgate is a popular source for company and licensing deal information. If you are interested in learning more, please do not hesitate to contact us and apply for a trial.

Visit our website and try Biotechgate: www.biotechgate.com

Venture Valuation
Kasernenstrasse 11
8004 Zurich
Switzerland

Phone: +41 (43) 321 86 60

Web: www.venturevaluation.com

Email: contact@venturevaluation.com



Copyright © 2023 Venture Valuation VV Ltd. All rights reserved. This report is provided for information purposes only. All information regarding financing rounds, deal summaries and merger and acquisition transactions was obtained from company websites, press-releases, conference profiles and different industry newsletters. The data contained in the tables and graphs can also be accessed on the Biotechgate website. All graphical information was provided via Biotechgate. While the information contained herein has been obtained from sources deemed reliable, Venture Valuation VV Ltd makes no guarantees that it is accurate, complete, timely, or sequential. For more information about Biotech companies, including deal, licensing and financing round details, please visit the Biotechgate website at www.biotechgate.com